Upacicalcet reduced parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism in PATH-1 and PATH-2
Company-reported PATH-1 and PATH-2 results found that upacicalcet reduced iPTH in hemodialysis patients with secondary hyperparathyroidism versus placebo.
Get the app